Flaxseed protein source sulfydryl peptide with lead damage protection and lead absorption inhibition effects, food, lead damage repairing agent, gene and application and preparation method of flaxseed protein source sulfydryl peptide
By extracting and enriching sulfhydryl peptides from flaxseed proteins, a flaxseed protein-derived sulfhydryl peptide with lead-binding characteristics was developed, which solved the side effects and safety problems of existing lead-repellent drug, and effectively reduced the accumulation of lead in the human body and damage, significantly reducing the concentration and damage of lead ions in cells.
Patent Information
- Application Number
- CN202410971391.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-08
Smart Images

Figure CN118909062A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of food, and specifically relates to a flaxseed protein-derived thiol peptide with the functions of protecting against lead damage and inhibiting lead absorption, food, a lead damage repair agent, a gene, and an application and a preparation method thereof. Background Art
[0002] Bioactive peptides are a special protein component that has a wide range of applications in cosmetics, food additives, health products and medicines as antimicrobial, antioxidant, antithrombotic and heavy metal damage inhibitors. These peptides can protect consumers’ health by regulating or improving chronic diseases and are used as important functional ingredients in health-promoting foods and nutraceuticals to prevent and control a variety of diseases due to their biological activity.
[0003] Plant protein peptides containing cysteine residues (containing sulfhydryl groups) as a kind of bioactive peptides have the ability to bind lead ions, which can reduce the lead concentration in the body of people with lead poisoning and relieve the symptoms of poisoning. Existing literature Woolf AD, Goldman R, Bellinger DC. Update on the Clinical Management of Childhood Lead Poisoning [J]. The Pediatric Clinics of North America, 2007, 54 (2): 271-294. It is recorded that plant protein peptides containing cysteine residues, i.e. sulfhydryl groups, have the ability to bind lead ions and can reduce the lead concentration in the body of people with lead poisoning. Existing literature Sun Yuan. Separation and enrichment of cysteine peptides from wheat gluten protein and their binding to lead ions [D]. Wuxi: Jiangnan University, 2021, records that cysteine peptides HCPs isolated from wheat gluten protein can bind to lead ions to form a stable conjugate.
[0004] In the prior art, the commonly used drugs for lead removal treatment are calcium disodium edetate and sodium dithiosulfate, which have the following defects: calcium disodium edetate Long-term use of calcium disodium edetate can cause serious damage to the patient's kidneys, and it can also react with other essential trace elements in the body (such as calcium, zinc, copper, magnesium, etc.), resulting in "over-complexation syndrome", causing patients to experience fatigue, weakness, loss of appetite, general soreness, nausea and other side effects. Sodium dithiosulfate is a low-toxic drug, but long-term use still has some side effects, mainly oral digestive tract symptoms such as abdominal cramps, nausea, vomiting, dizziness, headache, limb pain, fatigue, general soreness, etc.
[0005] Based on this, it is of great significance to develop effective and safe natural compounds to prevent excessive accumulation of lead in the human body. Plant-derived thiol-rich protein peptides may be used as alternatives to commonly used lead-removing drugs or as active ingredients in lead-damage protection foods. Using such natural compounds to prevent and control lead accumulation in the human body can provide safe and effective lead protection. Summary of the invention
[0006] In order to at least solve one or more of the technical problems mentioned above, an embodiment of the present invention provides a flaxseed protein-derived thiol peptide with lead damage protection and lead absorption inhibition effect, comprising at least one of the following peptides: a peptide composed of the amino acid sequence shown in SEQ ID No.1; a peptide composed of the amino acid sequence shown in SEQ ID No.2; a peptide composed of the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; a peptide composed of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a flaxseed protein-derived thiol peptide with lead binding properties.
[0007] According to one embodiment of the present invention, the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is a mixture comprising at least two of the following peptides: a peptide consisting of the amino acid sequence shown in SEQ ID No.1; a peptide consisting of the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a flaxseed protein-derived thiol peptide having lead binding properties.
[0008] According to one embodiment of the present invention, the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is a connector comprising at least two of the following peptides: a peptide consisting of the amino acid sequence shown in SEQ ID No.1; a peptide consisting of the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a flaxseed protein-derived thiol peptide having lead binding properties.
[0009] According to one embodiment of the present invention, an amino acid residue is connected to the N-terminal side and / or the C-terminal side of the peptide.
[0010] According to one embodiment of the present invention, the number of amino acid residues is any one of 10, 5, 4, 3, 2, and 1.
[0011] According to one embodiment of the present invention, the peptide is in the form of a salt, including an acid addition salt or a basic salt. The acid addition salt includes an inorganic salt and an organic acid salt. The basic salt includes an alkali metal salt and an alkaline earth metal salt.
[0012] According to another aspect of the present invention, a food is provided, the food comprising the aforementioned flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption.
[0013] According to one embodiment of the present invention, the food further comprises an additive, and the additive is selected from at least one of the following components: carbohydrates, proteins, lipids, vitamins, trace metals essential to organisms, and spices.
[0014] According to another aspect of the present invention, a lead damage repair agent is provided, wherein the lead damage repair agent uses the aforementioned flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption as an active ingredient.
[0015] According to another aspect of the present invention, the aforementioned flaxseed protein-derived thiol peptides, foods, and lead damage repair agents having the effects of protecting against lead damage and inhibiting lead absorption are used in protecting against lead damage.
[0016] According to another aspect of the present invention, an isolated gene is provided, which encodes the aforementioned flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption.
[0017] According to another aspect of the present invention, a method for preparing a flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is provided, comprising: a first step of removing impurities, crushing and defatting a low-temperature pressed flaxseed cake to obtain a defatted flaxseed cake powder; a second step of extracting flaxseed protein from the defatted flaxseed cake; a third step of enzymatically hydrolyzing the flaxseed protein to obtain a flaxseed protein-derived polypeptide; and a fourth step of enriching the thiol peptide from the flaxseed protein-derived polypeptide by covalent chromatography to obtain the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption.
[0018] The flaxseed protein-derived thiol peptide with lead damage protection and lead absorption inhibition effects according to the embodiments of the present invention has low toxicity, a high lead binding capacity, can reduce the lead ion content in cells and thus reduce cell damage, reduce the apoptosis rate of lead-damaged cells, reduce the inflammatory response of lead-damaged cells, alleviate the overexpression of MDA caused by lead damage, reduce cellular lead absorption, reduce the degradation of proteins related to cell tight junctions, and reduce the entry of lead ions into cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] By reading the following detailed description with reference to the accompanying drawings, the above and other objects, features and advantages of the exemplary embodiments of the present invention will become readily understood. In the accompanying drawings, several embodiments of the present invention are shown in an exemplary and non-limiting manner, and the same or corresponding reference numerals represent the same or corresponding parts, wherein:
[0020] Figure 1 A schematic diagram showing the toxic effects of lead ions, SCPs, and the drug dithiothreitol succinic acid (DMSA) of the AC group on Caco-2 cells;
[0021] Figure 2 Schematic diagram showing the effect of SCPs on the lead ion content in Caco-2 cells;
[0022] Figure 3 A schematic diagram showing the effect of SCPs on the apoptosis rate of Caco-2 cells;
[0023] Figure 4 Schematic diagram showing the effect of SCPs on Caco-2 cell apoptosis-related proteins Bcl-2, Bax, and CAS-3;
[0024] Figure 5 A schematic diagram showing the effect of SCPs on the levels of IL-6, IL-8, and TNF-α, the inflammatory indicators of Caco-2 cells;
[0025] Figure 6 The schematic diagram showing the effect of SCPs on the MDA content and the activities of SOD, CAT, and GSH-Px in Caco-2 cells;
[0026] Figure 7 A diagram of the Caco-2 cell Transwell model is shown;
[0027] Figure 8 Schematic diagram showing the effect of SCPs on the lead ion content on the AP / BL side of Caco-2 monolayer cells;
[0028] Fig. 9 Schematic diagram showing the effect of SCPs on the transmittance of Lucifer Yellow in Caco-2 cell monolayers;
[0029] Fig.10 Schematic diagram showing the effects of SCPs on tight junction-related proteins E-CAD, CLDN-4, ZO-1, and OCLN in Caco-2 monolayer cells. DETAILED DESCRIPTION
[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0031] It should be understood that the terms "include" and "comprising" used in the description and claims of the present invention indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.
[0032] It should also be understood that the terms used in this specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. As used in the specification of the present invention and the claims, the singular forms of "a", "an" and "the" are intended to include the plural forms unless the context clearly indicates otherwise. It should also be further understood that the term "and / or" used in the specification of the present invention and the claims refers to any combination of one or more of the associated listed items and all possible combinations, and includes these combinations.
[0033] The specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0034] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. These terms also apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[0035] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine.
[0036] The term "amino acid analog" refers to a compound having the same basic chemical structure as a naturally occurring amino acid (i.e., an alpha carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group), for example, homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
[0037] The term "amino acid mimetics" refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
[0038] In an embodiment of the present invention, a flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is provided, comprising at least one of the following peptides: a peptide composed of the amino acid sequence shown in SEQ ID No.1; a peptide composed of the amino acid sequence shown in SEQ ID No.2; a peptide composed of the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; a peptide composed of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide composed of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a flaxseed protein-derived thiol peptide having lead binding properties.
[0039] Specifically, the flaxseed protein-derived thiol peptides with the effects of protecting against lead damage and inhibiting lead absorption refer to flaxseed protein-derived thiol peptides (SCPs), which are separated from flaxseed protein. The flaxseed protein-derived thiol peptides with the effects of protecting against lead damage and inhibiting lead absorption include polypeptides with sequences shown in the amino acid sequence table SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, and may also include polypeptides with similar functions extracted from flaxseed protein. The amino acids in the above SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3 sequences also include amino acid analogs and amino acid mimetics. In the above sequences, each sequence can be independently a polypeptide, or a peptide can contain more than one sequence.
[0040] The above sequences can form three sulfhydryl-containing flaxseed polypeptides, namely:
[0041] Peptide I: GRGGQGGQGQQQQCEKQIQEQDYLRSCQQFLWEKVQKGGRS;
[0042] Peptide II: QGQQQQCEKQIQEQ;
[0043] Peptide III: IQQQGQQQEVERWVQQAKQVARDLPGQC.
[0044] The Cys14 and Cys27 sites provided by peptide I, the Cys7 site provided by peptide II, and the Cys28 site provided by peptide III can all provide oxygen atoms and sulfur atoms to bind to lead ions. The peptides of the present invention have a cysteine residue connected to the C-terminal side, i.e., contain free thiol groups, such as peptide I and peptide II, or have cysteine in the peptide chain, i.e., contain free thiol groups, such as peptide III. Free thiol groups have stronger lead binding capacity than amino groups or carboxyl groups, so the peptides of the present invention can be used to prevent lead poisoning and be used in food.
[0045] According to one embodiment of the present invention, the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is a mixture comprising at least two of the following peptides: a peptide consisting of the amino acid sequence shown in SEQ ID No.1; a peptide consisting of the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a flaxseed protein-derived thiol peptide having lead binding properties.
[0046] According to one embodiment of the present invention, the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is a connector comprising at least two of the following peptides: a peptide consisting of the amino acid sequence shown in SEQ ID No.1; a peptide consisting of the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; a peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; a flaxseed protein-derived thiol peptide having lead binding properties.
[0047] According to one embodiment of the present invention, the peptides shown in the sequences SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3 are connected to the N-terminal side and / or the C-terminal side with amino acid residues. The number of amino acid residues is any one of 10, 5, 4, 3, 2, and 1. The amino acids constituting the peptides may be L-type amino acids, D-type amino acids, or DL-type amino acids (the amino acids are a mixture of D-type and L-type amino acids).
[0048] When the peptide contains two or more asymmetric carbons, it can be any form of each enantiomer or diastereomer or a mixture thereof in any ratio. The separation of enantiomers or diastereomers can be performed using a normal column, an optically active column, or by introducing an optically active group and performing optical resolution in the form of a derivative, followed by removal of the optically active group.
[0049] According to one embodiment of the present invention, the polypeptide may be modified, and the amino terminus (N terminus) of the peptide may be a free amino group (NH2-) or an amino group modified with, for example, an acetyl group (CH3CO-). The carboxyl terminus (C terminus) of the peptide may be a free carboxyl group (-COOH) or a carboxyl group modified with, for example, an amide group. The amino acid residues of the peptide may be unmodified or may have modifications such as a phosphate group or a sugar chain.
[0050] According to one embodiment of the present invention, the peptide can be a solvate, which also includes water (in the case of a hydrate), methanol, ethanol, isopropanol, acetic acid, tetrahydrofuran, acetone, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, acetamide, ethylene glycol, propylene glycol, dimethoxyethane, etc.
[0051] According to one embodiment of the present invention, the peptide is in the form of a salt, including acid addition salts or basic salts, acid addition salts including inorganic salts and organic acid salts, and basic salts including alkali metal salts and alkaline earth metal salts. Acid addition salts include inorganic salts, such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and perchloric acid, citric acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid and p-toluenesulfonic acid. Organic acid salts include benzenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, etc. Basic salts include alkali metal salts, such as sodium, potassium and lithium, and alkaline earth metal salts, such as calcium and magnesium.
[0052] According to another aspect of the present invention, a food is provided, the food comprising the aforementioned flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption.
[0053] The food may be a natural product or a processed food that is not a natural product. Examples of food include beverages such as soft drinks, juices, milk drinks, soy milk drinks, tea drinks, and soups; processed foods such as ham, sausage, and fish processed foods; soy protein products such as granular soy protein and powdered soy protein; processed soy protein products such as fermented bean curd, tofu, and tofu burgers; fats such as edible fats, margarine, shortening, and emulsified fats; dairy products such as butter, fermented milk, milk powder, cream, and cheese; candies or candy materials such as chocolate, candies, chewing gum, soft candies, snacks, biscuits, whipped cream, custard, batter, cakes, puddings, jellies, buns, and dumplings; seasonings such as sauces, mayonnaise, ketchup, soy sauce, and yuzu sauce; bread and noodles; egg products such as mayonnaise; and dairy products such as dairy products, fermented dairy products, and yogurt drinks.
[0054] According to one embodiment of the present invention, the food further comprises an additive, and the additive is selected from at least one of the following components: carbohydrates, proteins, lipids, vitamins, trace metals essential to organisms, and spices.
[0055] Examples of the carbohydrate include sugars, processed starch (except dextrin, soluble starch, bismuth starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
[0056] Examples of proteins include whole milk powder, skimmed milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, B-lactoglobulin, α-lactalbumin, lactoferrin, soy protein, egg protein, meat protein and other animal and plant proteins, and their hydrolysates; butter, milk minerals, emulsifiable concentrate, whey, non-protein nitrogen, sialic acid, phospholipids, lactose and other milk-derived components, etc.
[0057] Examples of lipids include animal fats such as lard, fish oil, and their fractionated oils, hydrogenated oils, and transesterified oils; and vegetable fats such as palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, and their fractionated oils, hydrogenated oils, and transesterified oils.
[0058] Examples of vitamins include vitamin A, carotene, B vitamins, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline, folic acid, etc., and examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, etc.
[0059] The categories and types of food are not limited, and can be functional food, food for specific health care, food for specific purposes, nutritional functional food, health food, nursing food, and can also be snacks, lactic acid bacteria beverages, cheese, yogurt and other dairy products, condiments, etc. The shape of beverage food is not limited, and can be solid, liquid, liquid food, jelly, sheet, granule, capsule and other shapes of all beverage foods that can be circulated, and can also be added to various foods (milk, refreshing drinks, fermented milk, yogurt, cheese, bread, biscuits, salty crackers, pizza, formula milk powder, liquid food, patient food, nutritional food, frozen food, processed food and other commercially available foods, etc.). The manufacture of the above-mentioned beverage food can be carried out according to the conventional methods of those skilled in the art.
[0060] The amount of the aforementioned polypeptide added to the food can be adjusted according to demand, for example, the mass percentage can be 0.5% to 10%, 1% to 10%, 2% to 10%, 3% to 10%, 4% to 10%, 5% to 10%.
[0061] According to another aspect of the present invention, a lead damage repair agent is provided, which uses the aforementioned flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption as an active ingredient.
[0062] According to another aspect of the present invention, a flaxseed protein-derived thiol peptide, food, and lead damage repair agent having the effects of protecting against lead damage and inhibiting lead absorption are used in protecting against lead damage.
[0063] According to another aspect of the present invention, there is provided an isolated gene encoding the aforementioned flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption.
[0064] According to another aspect of the present invention, a method for preparing a flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption is provided, comprising: a first step of removing impurities, crushing and defatting a low-temperature pressed flaxseed cake to obtain a defatted flaxseed cake powder; a second step of extracting flaxseed protein from the defatted flaxseed cake; a third step of enzymatically hydrolyzing the flaxseed protein to obtain a flaxseed protein-derived polypeptide; and a fourth step of enriching the thiol peptide from the flaxseed protein-derived polypeptide by covalent chromatography to obtain the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption.
[0065] In the embodiments of the present invention, the sources of materials and reagents are as follows: low-temperature pressed flaxseed cake, commercially available; Protease M enzyme (46800U / g), Japan Amano Enzyme Preparation Co., Ltd.; Thiopropyl Crystarose 6Fast Flow gel, Wuhan Jingcheng Biotechnology Co., Ltd.; dithiothreitol (DTT), tris (hydroxymethylaminomethane) (Tris), Triton X-100, Shanghai MacLean Biochemical Technology Co., Ltd.; 2-2'-disulfide dipyridine, Shanghai Yien Chemical Technology Co., Ltd.; EDTA, Tianjin Damao Chemical Reagent Factory; glycine, HBSS (D-Hanks), Beijing Solebow Technology Co., Ltd.; n-hexane, nitric acid, sodium hydroxide, hydrochloric acid, etc. were purchased from Sinopharm Chemical Reagent Co., Ltd., and the above reagents were all analytical grade; chromatographic grade methanol, isopropanol, acetonitrile, Fisher Chemical Company, USA; Caco-2 cells, human IL6 ELISA kit, human IL8 ELISA kit and human TNFa ELISA kit, Shanghai Wenye Biotechnology Co., Ltd.; GAPDH, HRP-labeled anti-mouse IgG, and HRP-labeled anti-rabbit IgG, BBI Life Sciences Co., Ltd.; apoptosis detection kit, Wuhan Savell Biotechnology Co., Ltd.; CCK-8 detection kit and cell culture medium, Servicebio, USA; DMSO and Transwell chamber, Corning (Shanghai) Management Co., Ltd.; fetal bovine serum, Filinbio, USA; superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and malondialdehyde (MDA) kits were all purchased from Nanjing Jiancheng Biotechnology Co., Ltd.
[0066] Flaxseed is the seed of flax, which is flat and oval, and is an annual herbaceous plant belonging to the Linaceae family. Flaxseed is rich in α-linolenic acid, protein, dietary fiber and various trace nutrients. Flaxseed protein is mostly extracted from flaxseed and its cake after oil extraction by alkali extraction and acid precipitation. After appropriate enzymatic hydrolysis of flaxseed protein by protease, small molecular weight polypeptides and free amino acids are obtained.
[0067] The flaxseed protein-derived thiol peptide with the function of protecting against lead damage and inhibiting lead absorption in the present invention is obtained by subjecting flaxseed protein to enzymatic hydrolysis under specific conditions and then to enrichment treatment.
[0068] Example 1
[0069] Preparation of flaxseed protein-derived thiol peptides with lead damage protection and lead absorption inhibition effects
[0070] The preparation process of the flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption in the present invention comprises:
[0071] The first step is to remove impurities, crush and defatted the low temperature pressed flaxseed cake to obtain defatted flaxseed cake powder.
[0072] Low temperature pressed flax seed cake, commercially available. Remove impurities from low temperature pressed flax seed cake, crush it through an 80 mesh sieve, weigh the sample and place it in a beaker, add n-hexane at a solid-liquid ratio of 1:3 (g / mL), place it in a 25℃ water bath at 180r / min for 120min, and centrifuge it at 4000r / min for 15min to obtain the precipitate. Repeat the above operation twice, take out the precipitate and dry it, and you will get defatted flax seed cake powder.
[0073] In the second step, flaxseed protein is extracted from the defatted flaxseed cake.
[0074] Add defatted flaxseed meal to distilled water at a ratio of 1:20 (g / mL) and stir evenly, adjust the pH to 8.5, stir at 200r / min in a 50°C water bath for 2h, centrifuge at 4000r / min for 15min to obtain the supernatant. Adjust the pH of the supernatant to 4.2 and centrifuge at 4000r / min for 15min to obtain the precipitate, add distilled water at a ratio of 1:20 (g / mL), stir and disperse, centrifuge at 4000r / min for 15min, repeat the operation twice to wash the precipitate, add an appropriate amount of distilled water to the final precipitate to adjust the pH to 7.0 and freeze-dry to obtain flaxseed protein.
[0075] The third step is to enzymatically hydrolyze the flaxseed protein to obtain flaxseed protein source polypeptides.
[0076] Take flaxseed protein and ultrapure water and stir evenly, adjust the pH value of the solution, add Protease M enzyme in a constant temperature water bath and start enzymolysis at a fixed temperature. After the enzymolysis is completed, inactivate the enzyme in a water bath above 85°C for 15 minutes, then cool to room temperature, centrifuge at 4000r / min for 20 minutes, and finally collect the supernatant, freeze-dry, and obtain flaxseed protein source polypeptide.
[0077] In the present invention, the enzymatic hydrolysis temperature is preferably 50-60°C, more preferably 55°C.
[0078] The preferred enzymatic hydrolysis pH is 2.5-3.5, more preferably 3.0.
[0079] The preferred enzymatic hydrolysis time is 3-5 h, more preferably 4 h.
[0080] The preferred amount of enzyme added is 1%-3%, more preferably 2%.
[0081] Preferably, the enzymatic hydrolysis temperature is 50° C., the enzymatic hydrolysis time is 4 h, the enzymatic hydrolysis pH is 3.5, the enzyme addition amount is 2%, the sulfhydryl content of the enzymatic hydrolysis product is 13.37 μmol / g, and the protein recovery rate of the enzymatic hydrolysis product is 34.78%.
[0082] Protease M enzyme (46800 U / g) was provided by Amano Enzyme Co., Ltd., Japan.
[0083] The fourth step is to enrich the flaxseed protein-derived thiol peptides from the flaxseed protein-derived polypeptides by covalent chromatography to obtain the flaxseed protein-derived thiol peptides with the effects of protecting against lead damage and inhibiting lead absorption.
[0084] Covalent chromatography is a separation method that uses the covalent adsorption between solute molecules and chromatographic gel to separate the target product from other solute molecules. The ligand containing disulfide bonds is fixed on the chromatographic gel, and the thiol groups in the protein will covalently bind to the ligand to form disulfide and release 2-mercaptopyridine, thereby achieving selective enrichment of thiol-containing peptides. The thiol-containing peptides enriched on the gel column are desorbed by a reducing agent.
[0085] Specifically, 0.1 g of flaxseed protein source polypeptide was added into 50 mL of ultrapure water and stirred evenly, and filtered through a 0.45 μm filter membrane to prepare a loading sample.
[0086] Thiopropyl Crystarose 6 Fast Flow gel was swollen with ultrapure water, washed with 5-10 bed volumes of deionized water, and transferred to the chromatographic column. The absorbance of the effluent at 280 nm was recorded every 10 minutes using a UV detector.
[0087] The column environment was adjusted with 0.05 mol / L Tris-HCl buffer (pH 7.5) until the absorbance of the effluent was stable.
[0088] The sample was loaded to allow the thiol peptides in the sample to bind to the gel at a loading speed of 5 mL / min. After loading, the sample was washed with Tris-HCl buffer (pH 7.5) to remove the non-thiol peptide components that were not bound to the gel until the absorbance of the effluent was less than 0.1.
[0089] The thiol peptides bound to the gel were desorbed using 20 mmol / L DTT, and the desorption liquid was collected when the absorbance value changed. The collected desorption liquid was centrifuged at 4000 r / min for 20 min using a 1000Da ultrafiltration tube to remove DTT and salt ions in the desorption liquid. The ultrafiltrate was collected and freeze-dried to obtain flaxseed protein-derived thiol peptides (SCPs), i.e., flaxseed protein-derived thiol peptides with lead damage protection and lead absorption inhibition effects.
[0090] Thiopropyl Crystarose 6Fast Flow gel was provided by Wuhan Jingcheng Biotechnology Co., Ltd.
[0091] Dithiothreitol (DTT), 5,5'-dithiobis(NB), tris(hydroxymethyl)aminomethane (Tris), and Triton X-100 were provided by Shanghai MacLean Biochemical Technology Co., Ltd.
[0092] Example 2
[0093] Amino Acid Sequence Determination of Thiol Peptides SCPs from Flaxseed Protein
[0094] The amino acid sequence was determined by MALDI-TOF-MS / MS (tissue imaging technology of biological mass spectrometry) with C18 (3 μm, 100A) and Acclaim PePmap 100 (75 μm×2 cm) columns and mobile phases: phase A (0.1% FA aqueous solution) and phase B (0.1% FA acetonitrile solution).
[0095] The flaxseed protein-derived thiol peptide sample was dissolved in 50% acetonitrile and purified by column. The purified sample was dissolved in ultrapure water containing 0.1% trifluoroacetic acid. 0.1% trifluoroacetic acid and 5 mg / mL α-cyano-4-hydroxycinnamic acid were dissolved in 50% acetonitrile to form a matrix solution. The matrix solution and sample were mixed in a ratio of 1:1, and 1 μL of the mixed solution was spotted on the Scorce 384 target and then air-dried at room temperature for detection.
[0096] The sample was scanned by mass spectrometry with a scanning range of 350-2000u and a resolution of 70000 to generate a MALDI-MS map. The ions to be tested were selected for secondary scanning, with a scanning range depending on the automatic selection of the mass-to-charge ratio of the primary parent ion, an excitation fragmentation energy of 28%, a resolution of 17500, a temperature maintained at 360°C, an ion source voltage of 1800V, and an HCD fragmentation mode for analysis to obtain a MALDI-MS / MS spectrum, and the amino acid sequence of the sample was obtained by analysis.
[0097] Peptide I: GRGGQGGQGQQQQCEKQIQEQDYLRSCQQFLWEKVQKGGRS (SEQ ID NO.1). Molecular weight: 4794.29 Da, source: Linum usitatissimum [Q8LPD3_LINUS]
[0098] Peptide II: QGQQQQCEKQIQEQ (SEQ ID NO. 2). Molecular weight: 1760.80 Da, source: Linumusitatissimum [Q8LPD3_LINUS]
[0099] Peptide III: IQQQGQQQEVERWVQQAKQVARDLPGQC (SEQ ID NO. 3). Molecular weight: 3335.69 Da, source: Linum usitatissimum [Q8LPD3_LINUS]
[0100] Example 3
[0101] Determination of sulfhydryl content and lead binding capacity of sulfhydryl peptides SCPs derived from flaxseed protein
[0102] Determination of thiol content
[0103] Weigh 15 mg of flaxseed protein-derived thiol peptide SCPs sample and dissolve it in 5 mL Tris-Gly buffer (10.4 g Tris, 6.9 g glycine, 1.2 g EDTA, pH 8.0 per 1 L solution). Add 0.1 mL Ellman's reagent (0.2 g 2-nitrobenzoic acid dissolved in 50 mL Tris-Gly buffer), stir rapidly, react at room temperature in a dark place for 1 h, centrifuge the reacted sample at 4000 r / min for 10 min to obtain the supernatant. Measure the absorbance of the supernatant at 412 nm (using Tris-Gly buffer without protein sample as a control).
[0104] The calculation formula of thiol content: SH content (μmol / g) = 73.53 × A 412 ×C / D;
[0105] Among them, A 412 is the maximum absorbance of the sample at 412 nm; D is the dilution factor; C is the sample mass concentration (mg / mL).
[0106] Lead binding capacity determination
[0107] Dissolve 100 mg of sample in 10 mL of ultrapure water and stir with a magnetic stirrer for 1 h to completely dissolve the sample. Adjust the pH to 7.5 and add lead standard solution. Add ultrapure water to make the solution volume 20 mL. 2+ The mass concentration is 6 mg / L. The water bath temperature was adjusted to 37°C and the reaction was carried out at 150 r / min for 2 h. After the reaction, the supernatant was centrifuged at 10000 r / min for 3 min and the Pb content was determined by flame atomic absorption spectrophotometer. 2+ Mass concentration.
[0108] Pb 2+ Binding amount calculation formula: Q e =(C0-C1)×v / m;
[0109] Among them, Q ePb 2+ The binding amount is in mg / g; C0 is the Pb content in the initial solution. 2+ The mass concentration of Pb in the solution after the reaction is mg / L; C1 is the mass concentration of Pb in the solution after the reaction 2+ The mass concentration is in mg / L; m is the mass of flaxseed protein in g; v is the final solution volume in L.
[0110] Table 1 shows the results of the sulfhydryl content and lead binding capacity of flaxseed protein, flaxseed protein polypeptide (enzymatic peptide), and flaxseed protein-derived sulfhydryl peptides (SCPs) in Example 1, respectively, as detected by the above method. Different letters in each column indicate significant differences (P<0.05)
[0111] Table 1
[0112] Group Flaxseed protein Enzymatic peptide SCPs Thiol content / (μmol / g) <![CDATA[6.65±0.03 a ]]> <![CDATA[13.37±0.13 b ]]> <![CDATA[44.80±0.01 c ]]> Lead binding capacity / (mg / g) <![CDATA[6.38±0.11 a ]]> <![CDATA[11.40±0.55 b ]]> <![CDATA[24.98±0.18 c ]]>
[0113] As shown in Table 1, the sulfhydryl content of flaxseed protein increased after enzymatic hydrolysis, reaching 2.01 times that of flaxseed protein, and the lead binding capacity reached 1.79 times. The sulfhydryl content of SCPs obtained by Thiopropyl Crystarose 6Fast Flow covalent chromatography reached 3.35 times that of flaxseed protein enzymatic hydrolysis peptides, and the lead binding capacity was 2.19 times that of enzymatic hydrolysis peptides.
[0114] Thiopropyl Crystarose 6Fast Flow covalent chromatography can effectively enrich peptides containing thiol groups and obtain SCPs with higher lead binding capacity.
[0115] Example 4
[0116] Determination of the protective effect of SCPs on lead-damaged Caco-2 cells
[0117] Caco-2 cells were provided by Shanghai Wenye Biotechnology Co., Ltd.
[0118] Take the Caco-2 cells in the logarithmic growth phase and count the cells until 1×10 5 / mL, inoculated in a 96-well plate, the incubator temperature was adjusted to 37°C, the CO2 concentration was adjusted to 5%, the 96-well plate was placed in it and cultured for 24 hours, and the cultured cells were randomly divided into 5 groups: blank control group (NC), negative control group (Model), low-dose flaxseed peptide group (SCPs-L), high-dose flaxseed peptide group (SCPs-H), positive control group (AC), each group had 4 replicate wells.
[0119] The blank control group (NC) did not add any substances.
[0120] The negative control group (Model) was supplemented with 30 μM Pb2+ ;
[0121] The low-dose flaxseed peptide group (SCPs-L) was supplemented with 30 μM Pb 2+ , SCPs at a concentration of 0.4 mg / mL;
[0122] The high-dose flaxseed peptide group (SCPs-H) was supplemented with 30 μM Pb 2+ , SCPs at a concentration of 1.6 mg / mL;
[0123] The positive control group (AC) was supplemented with 30 μM Pb 2+ , DMSA at a concentration of 0.4 mg / mL.
[0124] 1. SCPs cytotoxicity test
[0125] The cells were digested and counted, and the cell concentration was adjusted to 5 × 10 4 Cells / mL, 100 μL (5000 cells) / well of cell suspension was prepared in a 96-well plate, and PBS was added to the outer circle to prevent evaporation of the culture medium. The culture plate was incubated in an incubator at 37°C and 5% CO2 for 12 hours. Different concentrations of Pb were added according to the grouping requirements. 2+ , SCPs or DMSA stock solution for 24 h, add CCK8 reagent to the well plate, 10 μL per well, and culture the 96-well plate in the incubator under the above conditions for 3 h. After the culture, the absorbance was measured at 450 nm using a DNM-9602 microplate reader.
[0126] The above method was used to determine the toxic effects of lead ions, SCPs and the drug dithiothreitol succinic acid (DMSA) in the AC group on Caco-2 cells.
[0127] Figure 1 A schematic diagram showing the toxic effects of lead ions, SCPs, and the AC group drug dithiothreitol succinic acid (DMSA) on Caco-2 cells.
[0128] like Figure 1 As shown, Pb 2+ The survival rate of Caco-2 cells was 79.17% at a concentration of 30 μM. SCPs at different concentrations had no significant effect on the survival rate of Caco-2 cells and had low toxicity. DMSA concentrations had no effect on the survival rate of Caco-2 cells.
[0129] 2. Effect of SCPs on the lead ion content in lead-damaged Caco-2 cells
[0130] The ICP-OES / MS method (inductively coupled plasma optical emission spectroscopy, inductively coupled plasma mass spectrometry) was used to detect the lead ion content in each group of samples.
[0131] Figure 2 Schematic diagram showing the effect of SCPs on the lead ion content in Caco-2 cells.
[0132] like Figure 2 As shown in the figure, the lead ion concentration in the cells of the Model group was significantly higher than that in the NC group (P<0.05). Compared with the Model group, the lead ion concentration in the cells of the SCPs-H group and the SCPs-L group was significantly lower (P<0.05). SCPs can prevent lead ions from entering cells by binding to lead ions, reduce the lead ion content in cells, and thus reduce cell damage. Different letters indicate significant differences (P<0.05).
[0133] 3. Effects of SCPs on apoptosis and apoptosis-related proteins in lead-damaged Caco-2 cells
[0134] The apoptosis detection of Caco-2 cells was carried out according to the experimental sequence of the apoptosis kit instructions.
[0135] Specifically, the cells to be tested were digested and suspended by repeated blowing, the suspension was centrifuged at 3000 r / min for 8 min, and the supernatant was skimmed off. PBS was placed in a 4°C refrigerator in advance, the refrigerated PBS was placed in the precipitate obtained by centrifugation, the cells were resuspended, the suspension was centrifuged at 3000 r / min for 8 min, and the supernatant was skimmed off.
[0136] Prepare 1×Annexin V binding buffer and PI working solution according to the kit: Take 1 mL of reagent C in the kit and add 4 mL of deionized water to obtain 1×Annexin V binding buffer that can be used 10 times. Take 5 μL of reagent B in the kit and add 45 μL of the above buffer to obtain PI working solution (100 μg / mL).
[0137] Add 1×Annexin V binding buffer to the treated cells, resuspend the cells, and count the cells so that their concentration is always greater than 1×10 6 / mL. Add the liquid that meets the counting conditions to the well plate, add 5μL of reagent A in the kit and 1μL of the above PI working solution to every 100μL, shake gently to disperse the solution evenly, place it at room temperature for 20min, take 400μL of 1×AnnexinV binding buffer and add it to the well plate. Sieve it before placing it in the flow tube, mix it evenly and place it on ice for detection.
[0138] Figure 3Schematic diagram showing the effect of SCPs on the apoptosis rate of Caco-2 cells.
[0139] like Figure 3 As shown in the figure, different letters indicate significant differences (P<0.05). Compared with the NC group, the apoptosis rate of Caco-2 cells in the Model group increased significantly (P<0.05), indicating that lead ions can damage Caco-2 cells and cause apoptosis. Compared with the Model group, the apoptosis rate of cells in the SCPs-H group and SCPs-L group was significantly reduced (P<0.05) and was dose-dependent with SCPs, indicating that SCPs can help reduce apoptosis of Caco-2 cells caused by lead damage.
[0140] Western blot was further used to detect apoptosis-related proteins, including B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), and caspase-3 (CAS-3).
[0141] Figure 4 A schematic diagram showing the effects of SCPs on Caco-2 cell apoptosis-related proteins Bcl-2, Bax, and CAS-3.
[0142] like Figure 4 Different letters indicate significant differences (P<0.05).
[0143] The Bcl-2 protein level in the Model group was significantly lower than that in the NC group (P<0.05).
[0144] Compared with the Model group, the Bcl-2 protein level in the SCPs-H and SCPs-L groups was significantly increased (P<0.05).
[0145] Compared with the NC group, the levels of Bax and CAS-3 proteins in the Model group were significantly increased (P<0.05).
[0146] Compared with the Model group, the levels of Bax and CAS-3 proteins in the SCPs-H and SCPs-L groups were significantly decreased (P<0.05).
[0147] The protein levels of Bax and CAS-3 in the SCPs-H group were reduced to no significant difference compared with the AC group.
[0148] This indicates that SCPs can alleviate lead-induced cell apoptosis by upregulating the level of Bcl-2 protein and downregulating the levels of Bax and CAS-3 proteins.
[0149] 4. Effects of SCPs on the inflammatory response of lead-induced Caco-2 cells
[0150] Elisa was used to detect the levels of IL-6, IL-8, and TNF-α, the inflammatory indicators of Caco-2 cells.
[0151] Figure 5 A schematic diagram showing the effect of SCPs on the levels of IL-6, IL-8, and TNF-α, the inflammatory indicators of Caco-2 cells.
[0152] like Figure 5 As shown in the figure, the levels of IL-6, IL-8, and TNF-α in the Model group were significantly higher than those in the NC group (P<0.05), indicating that lead can cause inflammatory response in Caco-2 cells.
[0153] Compared with the Model group, the levels of IL-6, IL-8, and TNF-α in the SCPs-H group and SCPs-L group were significantly decreased (P<0.05), indicating that SCPs can alleviate the inflammatory response by reducing the levels of inflammatory factors IL-6, IL-8, and TNF-α.
[0154] 5. Effects of SCPs on oxidative stress response of lead-induced Caco-2 cells
[0155] The cells in each group were fully lysed, and the cell lysate was taken to detect the contents of MDA, SOD, CAT, and GSH-Px using a kit.
[0156] Figure 6 A schematic diagram showing the effects of SCPs on the MDA content and SOD, CAT, and GSH-Px activities in Caco-2 cells.
[0157] like Figure 6 As shown, the MDA content of cells in the Model group was significantly higher than that in the NC group (P<0.05), indicating that lead can cause peroxidation reaction in Caco-2 cells.
[0158] Compared with the Model group, the MDA content of cells in the SCPs-H group and the SCPs-L group was significantly decreased (P<0.05), and the MDA content of the SCPs-H group was reduced to a level that was not significantly different from that of the AC group, indicating that SCPs can alleviate the overexpression of MDA caused by lead damage.
[0159] The enzyme activities of SOD, CAT, and GSH-Px in the Model group were significantly lower than those in the NC group (P<0.05), indicating that lead damage put Caco-2 cells in a state of oxidative stress.
[0160] Compared with the Model group, the activities of SOD, CAT, and GSH-Px in the SCPs-H and SCPs-L groups increased significantly to varying degrees (P<0.05), and the CAT activity in the SCPs-H group increased to a level that was not significantly different from that in the AC group. This suggests that SCPs can alleviate the oxidative stress response of Caco-2 cells by regulating the activity of antioxidant enzymes.
[0161] 6. Effects of SCPs on transmembrane transport of lead ions
[0162] Caco-2 cells were inoculated onto Transwell culture plates, and the Caco-2 cells fused on the porous polycarbonate membrane of the Transwell chamber to form a complete cell monolayer structure with tight junctions, thus establishing a Caco-2 cell monolayer model.
[0163] Figure 7 A diagram of the Caco-2 cell Transwell model is shown.
[0164] like Figure 7 As shown, lead ions and SCPs are added from the AP side and pass through the Caco-2 cell monolayer. A portion of the lead ions remain in the cells, while the other portion is transferred to the BL side through transmembrane transport.
[0165] The lead ion concentrations on the AP and BL sides of each group were detected respectively.
[0166] Figure 8 Schematic diagram showing the effect of SCPs on the lead ion content on the AP / BL side of Caco-2 monolayer cells.
[0167] like Figure 8 As shown, no lead ion concentration was detected on the AP / BL side in the NC group, indicating that both sides were pure culture medium without lead ions.
[0168] On the AP side, the lead ion concentration in the Model group was the lowest, indicating that a large amount of lead ions were absorbed by the cells, resulting in a decrease in the lead ion concentration in the upper layer of the cells.
[0169] Compared with the Model group, the lead ion concentration on the AP side of the SCPs-L and SCPs-H groups was significantly increased (P<0.05), indicating that SCPs added to the upper layer of cells can reduce the lead absorption of cells.
[0170] The lead ion concentration on the BL side of the SCPs-L and SCPs-H groups was significantly lower than that of the Model group, indicating that SCPs can reduce the number of lead ions passing through the Caco-2 monolayer cells and inhibit cellular lead absorption.
[0171] It is speculated that SCPs can fix lead ions by binding to lead ions, reduce the passage of lead ions through the Caco-2 monolayer cells, and inhibit the absorption of lead ions.
[0172] 7. Effects of SCPs on the permeability of lead-damaged cells
[0173] After washing the cells twice with HBSS, add 500μL / 1500μL HBSS solution to AP and BL respectively and incubate at 37℃ for 20min. Add 1500μL fresh HBSS solution to BL and replace with 500μL fluorescein sodium solution 20μg / ml in each well of AP. After culturing at 37℃ and 5% CO2 for 2h, collect the supernatant of BL and record it as 2h sample. Detect the sample with fluorescence microplate reader and calculate the transmittance of fluorescein yellow.
[0174] Fig. 9 Schematic diagram showing the effect of SCPs on the transmittance of Lucifer Yellow in Caco-2 cell monolayers.
[0175] like Fig. 9 As shown, the blank group is a Transwell polycarbonate membrane without Caco-2 cells, and its fluorescent yellow transmittance reaches 57.64%, indicating that the Transwell polycarbonate membrane has good permeability.
[0176] Compared with the blank group, the transmittance of fluorescent yellow in the NC group was significantly reduced to 1.78% (P<0.05), indicating that the differentiated Caco-2 cells were tightly connected, the monolayer structure was intact and had good density.
[0177] The fluorescent yellow transmittance of the Model group was significantly higher than that of the NC group (P<0.05), indicating that lead ions destroyed the tight junctions between cells and significantly increased the permeability of the cell monolayer.
[0178] Compared with the Model group, the fluorescent yellow transmittance of cells in the SCPs-L and SCPs-H groups was significantly reduced (P<0.05), and the fluorescent yellow transmittance of the SCPs-H group was reduced to a level that was not significantly different from that of the AC group. The results showed that SCPs can prevent lead ions from destroying the integrity of the cell monolayer structure, thereby inhibiting the absorption of lead ions by Caco-2 cells.
[0179] Western blot was used to detect the expression levels of cell tight junction-related proteins CLDN-4, ZO-1, OCLN, and E-CAD.
[0180] Fig.10 Schematic diagram showing the effects of SCPs on tight junction-related proteins E-CAD, CLDN-4, ZO-1, and OCLN in Caco-2 monolayer cells.
[0181] like Fig.10 As shown in the figure, compared with the NC group, the levels of cell tight junction-related proteins CLDN-4, ZO-1, and OCLN in the Model group were significantly reduced (P<0.05), indicating that lead ions can enter cells by destroying the tight junctions between cells and cause cell damage.
[0182] Compared with the Model group, the SCPs-L and SCPs-H groups significantly inhibited the downregulation of the expression of the three proteins (P<0.05). Among them, the CLDN-4, ZO-1, and OCLN protein levels in the SCPs-H group were significantly increased to the point where there was no significant difference from the AC group.
[0183] Compared with the NC group, the E-CAD protein level in the Model group was significantly increased (P<0.05), indicating that lead ions would enter the cells by competing for the transmembrane binding sites of calcium ions.
[0184] Compared with the Model group, the E-CAD protein levels in the SCPs-L and SCPs-H groups were controlled and significantly decreased (P<0.05), among which the E-CAD protein level in the SCPs-H group was reduced to a level that was not significantly different from that in the AC group.
[0185] From the above experiments, it can be inferred that after the lead ions act on the cells, on the one hand, they compete for calcium ion binding proteins, and on the other hand, they destroy the intestinal mucosal barrier by reducing the expression of cell tight junction-related proteins, and enter the intestinal epithelial cells. Some lead ions remain in the cells and cause damage to the cells, while the other part of the lead ions are transported outside the cells. SCPs can bind to lead ions at the top of the intestinal epithelial cells, maintain the integrity and tight junctions of the intestinal epithelial cells simulated by the Caco-2 cell monolayer by reducing the degradation of cell tight junction-related proteins, reduce the entry of lead ions into the cells, and thus inhibit the lead absorption of Caco-2 cells.
[0186] In the flaxseed protein-derived thiol peptides with lead damage protection and lead absorption inhibition effects of the present invention, SCPs can significantly reduce the lead ion content in Caco-2 cells, reduce lead-induced cell apoptosis by regulating the levels of apoptosis-related proteins Bcl-2, Bax, and CAS-3, reduce the expression of inflammatory factors IL-6, IL-8, and TNF-α, increase the activity of SOD, CAT, and GSH-Px, reduce the excessive release of MDA, and improve lead-induced inflammatory reactions and oxidative stress, thereby effectively protecting Caco-2 cells from lead damage.
[0187] In the Caco-2 cell Transwell model, SCPs can bind to lead ions on the AP side of Caco-2 cells, reducing the passage of lead ions through the Caco-2 monolayer. By regulating the abnormal expression of calcium ion binding protein E-CAD and upregulating the expression of tight junction-related proteins CLDN-4, ZO-1, and OCLN, the integrity and tight junctions of the Caco-2 cell monolayer structure are maintained, thereby inhibiting the lead absorption of Caco-2 cells.
[0188] Although multiple embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Those skilled in the art may conceive of many changes, modifications, and alternatives without departing from the thought and spirit of the present invention. It should be understood that in the process of practicing the present invention, various alternatives to the embodiments of the present invention described herein may be adopted. The appended claims are intended to define the scope of protection of the present invention, and therefore cover equivalents or alternatives within the scope of these claims.
[0189] The collection and acquisition of various data in this application complies with relevant laws and regulations and is authorized by the data provider. Any organization or individual that needs to obtain external data must obtain authorization in accordance with the law and ensure data security. It is not allowed to illegally collect, use, process, or transmit unauthorized or unprotected data, or to illegally buy, sell, provide, or disclose unauthorized or unprotected data.
Claims
1. A flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption, characterized in that: Contains at least one of the following peptides: A peptide consisting of the amino acid sequence shown in SEQ ID No. 1; A peptide consisting of the amino acid sequence shown in SEQ ID No.2; A peptide consisting of the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; A peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, and the amino acid sequence shown in SEQ ID No.3; Flaxseed protein-derived thiol peptides with lead-binding properties.
2. The flaxseed protein-derived thiol peptide according to claim 1, characterized in that: The flaxseed protein-derived thiol peptide is a mixture comprising at least two of the following peptides; A peptide consisting of the amino acid sequence shown in SEQ ID No. 1; A peptide consisting of the amino acid sequence shown in SEQ ID No.2; A peptide consisting of the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; A peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, and the amino acid sequence shown in SEQ ID No.3; Flaxseed protein-derived thiol peptides with lead-binding properties.
3. The flaxseed protein-derived thiol peptide according to claim 1, characterized in that: The flaxseed protein-derived thiol peptide is a linker comprising at least two of the following peptides; A peptide consisting of the amino acid sequence shown in SEQ ID No. 1; A peptide consisting of the amino acid sequence shown in SEQ ID No.2; A peptide consisting of the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.2; A peptide consisting of the amino acid sequence shown in SEQ ID No.1 and the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.2 and the amino acid sequence shown in SEQ ID No.3; A peptide consisting of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, and the amino acid sequence shown in SEQ ID No.3; Flaxseed protein-derived thiol peptides with lead-binding properties.
4. The flaxseed protein-derived thiol peptide according to any one of claims 1 to 3, characterized in that The N-terminal side and / or the C-terminal side of the peptide are connected with amino acid residues.
5. The flaxseed protein-derived thiol peptide according to claim 4, characterized in that: The number of the amino acid residues is any one of 10, 5, 4, 3, 2, and 1.
6. A food, characterized in that The food comprises the flaxseed protein-derived thiol peptide according to any one of claims 1 to 5.
7. A lead damage repair agent, characterized in that: The lead damage repair agent comprises the flaxseed protein-derived thiol peptide according to any one of claims 1 to 5 as an active ingredient.
8. Use of the flaxseed protein-derived thiol peptide according to any one of claims 1 to 5, the food according to claim 6, and the lead damage repairing agent according to claim 7 in protecting against lead damage.
9. An isolated gene, characterized in that The isolated gene encodes the flaxseed protein-derived thiol peptide according to any one of claims 1 to 5.
10. A method for preparing a flaxseed protein-derived thiol peptide having the effects of protecting against lead damage and inhibiting lead absorption, characterized in that: include: The first step is to remove impurities, crush and defatted the low-temperature pressed flaxseed cake to obtain defatted flaxseed cake powder; The second step is to extract flaxseed protein from the defatted flaxseed cake; The third step is to enzymatically hydrolyze the flaxseed protein to obtain flaxseed protein source polypeptides; The fourth step is to enrich the thiol peptides from the flaxseed protein source polypeptides by covalent chromatography to obtain the flaxseed protein source thiol peptides with the effects of protecting against lead damage and inhibiting lead absorption.
Citation Information
Patent Citations
Nutrition powder enriched with unsaturated fatty acid
CN106262877A
Method for preparing high-purity flaxseed cyclic peptide from flaxseed meal cake
CN114920797A
Flaxseed source cyclic peptide extract with anti-oxidation effect as well as preparation method and application of flaxseed source cyclic peptide extract
CN116621926A
Preparation method of sunflower seed meal protein
CN118058383A
Selenium-rich pleurotus eryngii hexapeptide for promoting lead excretion as well as preparation method and application of selenium-rich pleurotus eryngii hexapeptide
CN118666958A
